FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 323:1015-1021 October 11, 1990 Number 15 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. Zidovudine delays the progression of human immunodeficiency virus (HIV) infection but is associated with hematologic toxicity at high doses. Regimens are needed that preserve or enhance efficacy and reduce toxicity. Acyclovir has been reported to potentiate the effect of zidovudine on HIV in vitro. METHODS. We conducted a Phase II open-label, dose-escalating trial to evaluate the clinical and antiviral effects of zidovudine at low (300 mg daily, 28 subjects), medium (600 mg, 24 subjects), and high (1500 mg, 15 subjects) doses, either with or without acyclovir (4.8 g) by random assignment. The subjects had the acquired immunodeficiency syndrome (AIDS)-related complex, but not AIDS. All of them had either HIV p24 antigenemia or plasma viremia and CD4-lymphocyte counts of 200 to 500 per cubic millimeter when they began treatment. RESULTS. Performance scores and fatigue improved the most in the low- and medium-dose zidovudine groups (both P less than or equal to 0.025). Those assigned to low-dose zidovudine gained the most weight and had the greatest improvement in the mean CD4-lymphocyte count (from 321 per cubic millimeter at base line to 412 per cubic millimeter after 12 weeks, P = 0.01). The proportion of subjects in whom HIV antigenemia resolved, the decrease in the level of antigenemia, and the reduction in the plasma virus titers were similar at all three doses. Subjects assigned to receive the low or medium dose who subsequently crossed over to the 1500-mg dose (n = 19) did not have an increase in CD4-cell counts or a decline in levels of HIV antigen, but they did have dose-related toxicity. The addition of acyclovir to zidovudine was well tolerated, but it did not enhance any of zidovudine's antiretroviral effects. CONCLUSIONS. In this pilot study a very low dose of zidovudine (300 mg) had clinical and virologic effects similar to those of higher daily doses (600 and 1500 mg). The minimal effective dose of zidovudine for the treatment of HIV infection has yet to be determined, and further studies of very low daily doses are warranted.

Source Information

Department of Medicine, University of Washington School of Medicine, Seattle.

This article has been cited by other articles:

• Hurwitz, S. J., Asif, G., Kivel, N. M., Schinazi, R. F. (2008). Development of an Optimized Dose for Coformulation of Zidovudine with Drugs That Select for the K65R Mutation Using a Population Pharmacokinetic and Enzyme Kinetic Simulation Model. Antimicrob. Agents Chemother. 52: 4241-4250 [Abstract] [Full Text]  
• Flynn, P. M., Rodman, J., Lindsey, J. C., Robbins, B., Capparelli, E., Knapp, K. M., Rodriguez, J. F., McNamara, J., Serchuck, L., Heckman, B., Martinez, J., the PACTG P1012 Team, (2007). Intracellular Pharmacokinetics of Once versus Twice Daily Zidovudine and Lamivudine in Adolescents. Antimicrob. Agents Chemother. 51: 3516-3522 [Abstract] [Full Text]  
• Kewn, S., Wang, L. H., Hoggard, P. G., Rousseau, F., Hart, R., MacNeela, J. P., Khoo, S. H., Back, D. J. (2003). Enzymatic Assay for Measurement of Intracellular DXG Triphosphate Concentrations in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus Type 1-Infected Patients. Antimicrob. Agents Chemother. 47: 255-261 [Abstract] [Full Text]  
• Jing, N., De Clercq, E., Rando, R. F., Pallansch, L., Lackman-Smith, C., Lee, S., Hogan, M. E. (2000). Stability-Activity Relationships of a Family of G-tetrad Forming Oligonucleotides as Potent HIV Inhibitors. A BASIS FOR ANTI-HIV DRUG DESIGN. J. Biol. Chem. 275: 3421-3430 [Abstract] [Full Text]  
• Drusano, G. L., Stein, D. S. (1998). Mathematical Modeling of the Interrelationship of CD4 Lymphocyte Count and Viral Load Changes Induced by the Protease Inhibitor Indinavir. Antimicrob. Agents Chemother. 42: 358-361 [Abstract] [Full Text]  
• Hirsch, M. S., D'Aquila, R. T. (1993). Therapy for Human Immunodeficiency Virus Infection. NEJM 328: 1686-1695 [Full Text]  
• Barohn, R. J., Gronseth, G. S., LeForce, B. R., McVey, A. L., McGuire, S. A., Butzin, C. A., King, R. B. (1993). Peripheral Nervous System Involvement in a Large Cohort of Human Immunodeficiency Virus--Infected Individuals. Arch Neurol 50: 167-171 [Abstract]  
• McLeod, G. X., Hammer, S. M. (1992). Zidovudine: Five Years Later. ANN INTERN MED 117: 487-501 [Abstract]  
• Drusano, G. L., Yuen, G. J., Lambert, J. S., Seidlin, M., Dolin, R., Valentine, F. T. (1992). Relationship between Dideoxyinosine Exposure, CD4 Counts, and p24 Antigen Levels in Human Immunodeficiency Virus Infection: A Phase I Trial. ANN INTERN MED 116: 562-566 [Abstract]  
• Jabs, D. A. (1992). Treatment of Cytomegalovirus Retinitis--1992. Arch Ophthalmol 110: 185-187 [Abstract]  
• Tartaglione, T. A., Collier, A. C., Coombs, R. W., Opheim, K. E., Cummings, D. K., Mackay, S. R., Benedetti, J., Corey, L. (1991). Acquired Immunodeficiency Syndrome Cerebrospinal Fluid Findings in Patients Before and During Long-term Oral Zidovudine Therapy. Arch Neurol 48: 695-699 [Abstract]  
• (1990). AN EVEN LOWER DOSE OF ZIDOVUDINE MAY BE EFFECTIVE IN ARC. JWatch General 1990: 5-5 [Full Text]